Document Detail


Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan.
MedLine Citation:
PMID:  22445709     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Cinacalcet effectively reduces elevated levels of parathyroid hormone (PTH) in patients with secondary hyperparathyroidism (SHPT), even those with severe disease for whom parathyroidectomy can be the treatment of choice. The objective of this study was to estimate the cost-effectiveness of cinacalcet treatment in hemodialysis patients with severe SHPT in Japan.
STUDY DESIGN: Cost-effectiveness analysis.
SETTING & POPULATION: Patients with severe SHPT (intact PTH >500 pg/mL) who were receiving hemodialysis in Japan.
MODEL, PERSPECTIVE, & TIMEFRAME: A Markov model was constructed from the health care system perspective in Japan. Patients were followed up over their lifetime. Dialysis costs were not included in the base case.
INTERVENTION: Cinacalcet as an addition to conventional treatment compared to conventional treatment alone. In both arms, patients underwent parathyroidectomy if intact PTH level was >500 pg/mL for 6 months and they were eligible for surgery.
OUTCOMES: Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs).
RESULTS: ICERs for cinacalcet for those who were eligible for surgery and those who were not were $352,631/QALY gained and $21,613/QALY gained, respectively. Sensitivity and scenario analyses showed that results were fairly robust to variations in model parameters and assumptions. In the probabilistic sensitivity analysis, cinacalcet was cost-effective in only 0.9% of simulations for those eligible for surgery, but in more than 99.9% of simulations for those ineligible for surgery, if society would be willing to pay $50,000 per additional QALY.
LIMITATIONS: Data for the long-term effect of cinacalcet on patient-level outcomes are limited. The model predicted rates for clinical events using data for the surrogate biochemical end points.
CONCLUSIONS: The use of cinacalcet to treat severe SHPT is likely to be cost-effective for only those who cannot undergo parathyroid surgery for medical or personal reasons.
Authors:
Hirotaka Komaba; Kensuke Moriwaki; Shunsuke Goto; Shunsuke Yamada; Masatomo Taniguchi; Takatoshi Kakuta; Isao Kamae; Masafumi Fukagawa
Related Documents :
18227419 - Neuropathy progression in charcot-marie-tooth disease type 1a.
22397219 - Endoscopic treatment of benign and malignant strictures of the cervical esophagus and h...
22314429 - Comparison of two non-contemporaneous hcv-liver transplant cohorts: strategies to impro...
25174319 - Endoscopic lift of the maxillary sinus floor in beagles.
22762719 - Usefulness of epicardial adipose tissue as predictor of cardiovascular events in patien...
19555539 - Management and treatment outcomes of tuberculous patients, eastern paris, france, 2004.
10694619 - Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, pr...
21740159 - Relaxin does not rescue coronal suture fusion in craniosynostotic rabbits.
23295729 - Predictors of listening capabilities and patient satisfaction after stapes surgery in o...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-03-24
Journal Detail:
Title:  American journal of kidney diseases : the official journal of the National Kidney Foundation     Volume:  60     ISSN:  1523-6838     ISO Abbreviation:  Am. J. Kidney Dis.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-18     Completed Date:  2012-09-28     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  8110075     Medline TA:  Am J Kidney Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  262-71     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Affiliation:
Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Cost-Benefit Analysis
Costs and Cost Analysis
Female
Humans
Hyperparathyroidism, Secondary / drug therapy*,  economics,  etiology
Japan
Kidney Failure, Chronic / complications
Male
Markov Chains
Middle Aged
Monte Carlo Method
Naphthalenes / economics*,  therapeutic use*
Parathyroidectomy
Quality-Adjusted Life Years
Renal Dialysis
Chemical
Reg. No./Substance:
0/Naphthalenes; UAZ6V7728S/cinacalcet
Comments/Corrections
Comment In:
Am J Kidney Dis. 2012 Aug;60(2):179-81   [PMID:  22805518 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  GFR and Cardiovascular Outcomes After Acute Myocardial Infarction: Results From the Korea Acute Myoc...
Next Document:  Photon emission probabilities of (176)Lu.